

# PRospective obsErvational Study to quantify thE buRden of illness of Vasospasm and delayed cErebral ischaemia (PRESERVE)

**First published:** 30/08/2022

**Last updated:** 23/04/2024

Study

Finalised

## Administrative details

### EU PAS number

EUPAS48706

---

### Study ID

49584

---

### DARWIN EU® study

No

---

### Study countries

 France

---

### Study description

**\*\*This study was terminated prematurely for reasons unrelated to any safety or patient-related concerns, as no data was collected no report will be produced \*\***

This is a prospective, nationwide, multi-centre observational cohort study which aims to assess the humanistic burden of illness associated with the development of delayed cerebral ischaemia (DCI) following aneurysmal subarachnoid hemorrhage (aSAH). The study will utilise survey methods to administer validated and bespoke questionnaires to patients with aSAH and their principal caregiver. A total of 400 participants with aSAH will be recruited by eleven centres across France. Participating hospitals will provide details regarding the aSAH event and clinically relevant details by completing an electronic case report form at patient hospital discharge. After discharge, patient and caregiver questionnaires will be administered at 3-, 6- and 12-months following date of patient aneurysmal securing procedure. The participants functional status, activities of daily living, employment and productivity, as well as quality of life will be assessed. In addition, the participant's caregiver burden and work and productivity will be assessed.

---

## **Study status**

Finalised

## Research institutions and networks

### Institutions

[Evidence and Access/Analytica Laser, Certara](#)



France



United Kingdom (Northern Ireland)

**First published:** 24/05/2021

**Last updated:** 06/03/2024

**Institution**

**Non-Pharmaceutical company**

**ENCePP partner**

**Multiple centres: 11 centres are involved in the study**

## Networks

**BELIEVE Scientific Committee**

## Contact details

### **Study institution contact**

Louis Puybasset [believe.project@certara.com](mailto:believe.project@certara.com)

**Study contact**

[believe.project@certara.com](mailto:believe.project@certara.com)

### **Primary lead investigator**

Louis Puybasset

**Primary lead investigator**

## Study timelines

**Date when funding contract was signed**

Planned: 23/11/2021

Actual: 23/11/2021

---

**Study start date**

Planned: 14/11/2022

Actual: 06/02/2023

---

**Data analysis start date**

Planned: 01/06/2024

Actual: 06/02/2023

---

**Date of final study report**

Planned: 31/12/2024

Actual: 06/02/2023

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Idorsia Pharmaceuticals Ltd

## Regulatory

**Was the study required by a regulatory body?**

No

---

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

**Study topic:**

Disease /health condition

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Assessment of risk minimisation measure implementation or effectiveness

Disease epidemiology

**Data collection methods:**

Combined primary data collection and secondary use of data

---

**Main study objective:**

To assess and compare the humanistic burden of illness associated with the development of delayed cerebral ischaemia following aneurysmal subarachnoid hemorrhage among patients and their caregivers.

## Study Design

## **Non-interventional study design**

Cohort

Cross-sectional

Other

---

## **Non-interventional study design, other**

Prospective, nationwide, multi-centre observational study

# Study drug and medical condition

## **Medical condition to be studied**

Subarachnoid haemorrhage

---

## **Additional medical condition(s)**

Aneurysmal subarachnoid hemorrhage

# Population studied

## **Short description of the study population**

Patients with aneurysmal subarachnoid hemorrhage (aSAH) identified from 11 centres across France.

---

## **Age groups**

- Adults (18 to < 46 years)
  - Adults (46 to < 65 years)
  - Adults (65 to < 75 years)
  - Adults (75 to < 85 years)
  - Adults (85 years and over)
-

## **Special population of interest**

Other

---

## **Special population of interest, other**

Patients with subarachnoid haemorrhage

---

## **Estimated number of subjects**

400

# Study design details

## **Outcomes**

The following patient outcomes will be assessed and compared at each follow-up time-point, unless otherwise stated: - Functional impairment - Cognitive impairment - Health-related quality of life - Activities of daily living - Mood - Return to work among employed patients at 12 months - Return to school/education among patients at 12 months - Work productivity/absenteeism at 12 months, The following caregiver outcomes will be assessed and compared at each follow-up time-point, unless otherwise stated: - Health-related quality of life - Caregiver subjective burden - Caregiver objective burden - Mood - Return to work, where relevant at 12 months - Return to school/education, where relevant at 12 months - Work productivity/absenteeism, where relevant at 12 months

---

## **Data analysis plan**

Descriptive statistics will be used to describe and compare participant demographic and clinical characteristics according to patient DCI status. Propensity score methods will be used to balance differences between patients and the caregivers of patients who did and did not develop DCI. Propensity scores will be derived for each participant using a logistic regression model

including pre-specified confounders such as age, World Federation of Neurosurgical Societies grade, Modified Fisher scale, aneurysm size, aneurysm-securing procedure. Thereafter, the groups will be balanced using the Inverse Probability of Treatment Weighting (IPTW). Appropriate models (mixed effects logistic regression for binary variables, mixed effects linear regression model for continuous variables and count or rate variables) will be used to compare patient and caregiver outcomes according to DCI status, accounting for IPTW.

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

### **Composition of steering group and observers**

[Composition Scientific Committee.pdf](#) (34.96 KB)

---

## Data sources

### **Data sources (types)**

[Other](#)

---

### **Data sources (types), other**

Prospective patient-based data collection, Prospective caregiver-based data collection  
Medical chart review

## Use of a Common Data Model (CDM)

## **CDM mapping**

No

## Data quality specifications

### **Check conformance**

Unknown

---

### **Check completeness**

Unknown

---

### **Check stability**

Unknown

---

### **Check logical consistency**

Unknown

## Data characterisation

### **Data characterisation conducted**

No